Repositorio Dspace

Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study

Mostrar el registro sencillo del ítem

dc.contributor.author Bellido, Virginia
dc.contributor.author Cebrián-Cuenca, Ana-María
dc.contributor.author Morales, Cristobal
dc.contributor.author de-las-Hazas, Alberto-S
dc.contributor.author Soto-González, Alfonso
dc.contributor.author Morer-Linan, Carla
dc.contributor.author Borrachero-Guijarro, José-Miguel
dc.contributor.author Cuatrecases, Gabriel
dc.contributor.author García, Elena-L
dc.contributor.author López-Fernández, Judith
dc.contributor.author Lozano-García, Silvia
dc.contributor.author Bayon, Alvaro-M
dc.contributor.author Nino-Azcarate, Cristina-M
dc.contributor.author Laclaustra, Oscar
dc.contributor.author Fuentealba, Paulina
dc.date.accessioned 2026-10-28T08:18:24Z
dc.date.available 2026-10-28T08:18:24Z
dc.date.issued 2026-09
dc.identifier.citation Bellido V, Cebrián A, Morales C, De Las Hazas AS, Soto-Gonzalez A, Morer-Liñan C, et al. Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study. Diabetes Ther. septiembre de 2026;17(9):1385-405. doi:10.1007/s13300-026-01903-2
dc.identifier.issn 1869-6953
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29075
dc.description.abstract INTRODUCTION: Hypoglycemia is a common complication in people with type 2 diabetes mellitus (T2DM) treated with basal insulin, yet its true prevalence in real-world primary care remains underexplored. This study used blinded continuous glucose monitoring (CGM) to assess glycemic patterns in patients with T2DM on basal insulin-supported oral therapy (BOT) with insulin glargine 100 U/mL (Gla-100) in Spain. METHODS: GPDetect was a prospective, multicenter, observational study in adults with T2DM treated with Gla-100 for ? 6 months in primary care. Participants underwent 14 days of blinded CGM (FreeStyle Libre(®) Pro iQ(®)). The primary objective of the present study was to estimate the proportion of patients with T2DM treated with Gla-100 whose TBR (glucose < 70 mg/dL) exceeded the internationally recommended threshold of 4%. Secondary endpoints included time in range (TIR), time above range (TAR), episodes of clinically significant hypoglycemia (< 54 mg/dL), cognitive function (MMSE), and fear of hypoglycemia (EsHFS). RESULTS: Among 136 patients (mean age 69 years), 16.9% had TBR > 4%, with a higher prevalence at night (23.5%) than during the day (12.5%). Clinically significant hypoglycemia (< 54 mg/dL > 1%) occurred in 8.8% of patients. Hyperglycemia was common: 46.3% spent > 25% of the day between 181-250 mg/dL, and 28.7% spent time > 250 mg/dL. Only 55.9% achieved TIR ? 70%. Patients receiving SGLT2i had lower mean glucose and EsHFS scores. Cognitive impairment (MMSE < 23) was associated with longer hypoglycemia duration. CONCLUSIONS: Blinded CGM revealed a relevant burden of unrecognized hypoglycemia-particularly nocturnal-as well as daytime hyperglycemia in patients with T2DM treated with Gla-100 in primary care. These results support the clinical value of CGM in informing treatment decisions and improving individualized diabetes management.
dc.language.iso eng
dc.publisher SPRINGER HEIDELBERG
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional 
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es  *
dc.title Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42554785
dc.relation.publisherversion https://link.springer.com/10.1007/s13300-026-01903-2
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1007/s13300-026-01903-2
dc.journal.title Diabetes Therapy
dc.identifier.essn 1869-6961


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional  Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional 

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta